Premium
Myasthenia gravis after botulinum toxin a for Meige syndrome
Author(s) -
Tarsy Daniel,
Bhattacharyya Neil,
Borodic Gary
Publication year - 2000
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/1531-8257(200007)15:4<736::aid-mds1023>3.0.co;2-9
Subject(s) - medical school , bhattacharyya distance , medicine , gerontology , medical education , artificial intelligence , computer science
Botulinum toxin A (BTX-A) produces muscle weakness by blocking presynaptic release of acetylcholine at the neuromuscular junction. Following treatment with usual clinical doses, weakness is limited to local or adjacent muscles without clinically important effects on muscles in other body regions. However, abnormal neuromuscular transmission and remote type II muscle atrophy 6 without clinical weakness have been identified in muscles remote from the site of BTX-A injection. Recently, several patients with underlying neurologic disorders have been reported in whom BTX-A administration has produced exaggerated muscle weakness. 7–11 We are reporting follow-up information concerning a previously reported patient with Meige syndrome who developed acute, generalized myasthenia gravis immediately after BTX-A administration.